M. Desilvio

发表

Reengineering the New Product Development Process: A Framework for Innovation and Flexibility in High Technology Firms

Varun Grover, Manoj K. Malhotra, M. Desilvio, 1996 .

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

Daniel W. Miller, A. Zietman, M. Desilvio, 2005, JAMA.

Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.

M. Desilvio, N. Spector, M. Cristofanilli, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Measurement of Plasma-Derived Substance P: Biological, Methodological, and Statistical Considerations

M. Desilvio, A. Lackner, A. Cnaan, 2006, Clinical and Vaccine Immunology.

Progression free survival (PFS) after whole-pelvic (WP) vs. mini-pelvic (MP) or prostate only (PO) radiotherapy (RT): A subset analysis of RTOG 9413, a Phase III prospective randomized trial using neoadjuvant and concurrent (N&CHT)

Charles R. Thomas, R. Valicenti, M. Desilvio, 2004 .

Results of a prospective multi-institutional phase II trial (RTOG 98–05) of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate

W. R. Lee, D. Grignon, H. Sandler, 2004 .

Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: an analysis of RTOG 92–02

H. Sandler, M. Desilvio, W. Shipley, 2003 .

Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

Charles R. Thomas, D. Grignon, M. Roach, 2006, International journal of radiation oncology, biology, physics.

Final overall survival analysis of a phase II trial evaluating vinorelbine and lapatinib in women with ErbB2 overexpressing metastatic breast cancer.

M. Desilvio, B. Karaszewska, P. Potemski, 2015, Breast.

Phase II study of lapatinib in combination with vinorelbine , as first or second-line therapy in women with HER 2 overexpressing metastatic breast cancer

M. Desilvio, H. Chew, L. Schwartzberg, 2014 .

Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer

M. Desilvio, H. Chew, L. Schwartzberg, 2014, SpringerPlus.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

MDM2 as a predictor of prostate carcinoma outcome

D. Grignon, M. Hammond, H. Sandler, 2005, Cancer.

An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13

Charles R. Thomas, Christopher U. Jones, R. Valicenti, 2005 .

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

K. Rahbar, M. Morris, B. Krause, 2021, The New England journal of medicine.

Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14.

R. Ivker, M. Desilvio, B. Movsas, 2008, Journal of palliative medicine.

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

L. Bosserman, M. Desilvio, L. Hart, 2012, Breast Cancer Research and Treatment.

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone

Bing-he Xu, M. Desilvio, Zefei Jiang, 2014, Breast Cancer Research.

Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer

E. Frangou, H. Gabra, M. Desilvio, 2018, Clinical Cancer Research.

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

M. Hammond, H. Sandler, M. Desilvio, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10.

R. Jove, J. Torres-Roca, H. Sandler, 2007, Urology.

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

R K Valicenti, M Machtay, C. Jones, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surrogate end points for prostate cancer: what is prostate-specific antigen telling us?

H. Sandler, M. Desilvio, 2003, Journal of the National Cancer Institute.

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

H. Gómez, Bing-he Xu, M. Desilvio, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.

John H Suh, Benjamin Movsas, Charles S Cleeland, 2005, Journal of the National Cancer Institute.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

S. Margolin, M. Desilvio, V. Semiglazov, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer

M. Desilvio, B. Karaszewska, P. Potemski, 2014, Breast Cancer Research and Treatment.

A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).

M. Desilvio, B. Karaszewska, P. Potemski, 2011 .

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

K. Rahbar, M. Morris, B. Krause, 2021 .

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.

P. LoRusso, M. Desilvio, S. Johnston, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuing evidence for poorer treatment outcomes for single male patients: retreatment data from RTOG 97-14.

J. Coyne, M. Desilvio, N. Janjan, 2005, International journal of radiation oncology, biology, physics.

Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.

M. Espié, M. Desilvio, H. Burris, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

M. Desilvio, A. Manikhas, S. Tjulandin, 2010, Oncology.

Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.

D. Grignon, H. Sandler, M. Desilvio, 2007, International journal of radiation oncology, biology, physics.

H. Sandler, T. Pisansky, M. Desilvio, 2005, International journal of radiation oncology, biology, physics.

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.

K. Blackwell, M. Desilvio, S. Johnston, 2009, The Lancet. Oncology.

Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02.

H. Sandler, R. Valicenti, M. Desilvio, 2006, International journal of radiation oncology, biology, physics.

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.

Charles R. Thomas, Mack Roach, Sucha Asbell, 2007, International journal of radiation oncology, biology, physics.

K. Rahbar, M. Morris, B. Krause, 2021, Annals of Oncology.

Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.

D. Grignon, Min Zhang, H. Sandler, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.

T. McDonnell, M. Hammond, H. Sandler, 2006, International journal of radiation oncology, biology, physics.

Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).

D. Grignon, H. Sandler, T. Pisansky, 2007, International journal of radiation oncology, biology, physics.

Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10.

P. Rubin, M. Desilvio, W. Sause, 2006, International journal of radiation oncology, biology, physics.

Accessory os fibulare avulsion secondary to the inversion ankle injury.

M. Desilvio, T. H. Bowlus, S. Korman, 1980, Journal of the American Podiatry Association.

Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)

M. Desilvio, V. Semiglazov, X. Pivot, 2012 .

A randomized trial comparing conventional dose (70.2GyE) and high-dose (79.2GyE) conformal radiation in early stage adenocarcinoma of the prostate: Results of an interim analysis of PROG 95–09

Judy Adams, B. Berkey, Jerry D. Slater, 2004 .

Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups.

D. Kuban, M. Zelefsky, A. Zietman, 2006, International Journal of Radiation Oncology, Biology, Physics.

A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019.

H. Sandler, M. Kuettel, M. Desilvio, 2006, International journal of radiation oncology, biology, physics.

Bing-he Xu, M. Desilvio, Zefei Jiang, 2014, Breast Cancer Research.

Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 9714

M. Desilvio, B. Movsas, M. Roach, 2004 .

Phase I II T rial C omparing W hole-Pelvic V ersus P rostate-Only Radiotherapy a nd N eoadjuvant V ersus A djuvant C ombined Androgen S uppression: R adiation T herapy O ncology Group 9 413

C. Jones, M. Desilvio, M. Roach, 2003 .

K. Rahbar, M. Morris, M. Desilvio, 2023, The Lancet. Oncology.

5050 POSTER Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients

Bing-he Xu, M. Desilvio, B. Newstat, 2011 .

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

H. Gómez, Bing-he Xu, M. Desilvio, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast cancer, early stage

M. Espié, C. Mermel, R. Gelber, 2012 .